Navidea Biopharmaceuticals Inc. (NAVB) News Nov 14, 2014,

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 11:19 AM

Navidea Biopharmaceuticals Inc. (NAVB) News Nov 14, 2014, 4:28 p.m.
MarketWatch News on NAVB
Navidea Biopharmaceuticals falls 8% in premarket 7:51 a.m. Dec. 3, 2012 - Steve Gelsi
Tuesday’s biggest gaining and declining stocks 3:55 p.m. Sept. 18, 2012 - MarketWatch
Tuesday’s top gaining and declining stocks 3:57 p.m. Sept. 11, 2012 - MarketWatch
Navidea Biopharmaceuticals down 32% in premarket 7:47 a.m. Sept. 11, 2012 - Steve Gelsi
Hot stocks to watch 6:32 a.m. Sept. 11, 2012 - MarketWatch.com
Stocks to watch Tuesday: Sonoco, Navidea, Thor 5:58 a.m. Sept. 11, 2012 - MarketWatch
Shuffle Master, Navidea shares drop after hours 4:59 p.m. Sept. 10, 2012 - Carla Mozee
Navidea shares slide 37% in trading after hours 3:29 p.m. Sept. 10, 2012 - Carla Mozee
In focus: Gathering strength 6:23 p.m. July 11, 2012 - Lawrence G. McMillan
Tuesday’s biggest gaining and declining stocks 4:16 p.m. April 3, 2012 - Kate Gibson
Advertisement
Other News on NAVB
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak 4:24 p.m. Nov. 13, 2014 - Seeking Alpha
10-Q: NAVIDEA BIOPHARMACEUTICALS, INC. 5:02 p.m. Nov. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Rick Gonzalez on Q3 2014 Results - Earnings Call Transcript 5:40 a.m. Nov. 8, 2014 - Seeking Alpha
Navidea Biopharmaceuticals Q3: What's Going On With Lymphoseek? 9:22 a.m. Nov. 7, 2014 - Seeking Alpha
Navidea Biopharmaceuticals (NAVB) Q3 2014 Results - Earnings Call Webcast 8:25 a.m. Nov. 6, 2014 - Seeking Alpha
Notable earnings before Thursday’s open 5:30 p.m. Nov. 5, 2014 - Seeking Alpha
FDA approves expanded label for Lymphoseek 6:30 a.m. Oct. 15, 2014 - Seeking Alpha
PDUFA date approaches for Lymphoseek expanded label 10:16 a.m. Oct. 8, 2014 - Seeking Alpha
Should You Buy Navidea Biopharmaceuticals? 9:30 a.m. Sept. 30, 2014 - Seeking Alpha
Europe Ad Comm supports Lymphoseek approval 9:00 a.m. Sept. 26, 2014 - Seeking Alpha
Navidea snags SBIR grant 7:18 a.m. Sept. 23, 2014 - Seeking Alpha
FDA tags Lymphoseek an Orphan Drug 4:16 p.m. Sept. 18, 2014 - Seeking Alpha
Should Navidea Biopharmaceuticals (NAVB) Be On Your Radar Now? - Tale of the Tape 7:55 a.m. Sept. 10, 2014 - Zacks.com
A Seismic Shift To Boost Biotech Stocks 9:00 a.m. Sept. 9, 2014 - InvestorPlace.com
Steve Brozak: Big-Picture Biotech Stocks Are the Future 9:00 a.m. Sept. 9, 2014 - InvestorPlace.com
Week In Review: DXY Receives $70 Million Investment From Tencent 12:37 a.m. Sept. 8, 2014 - Seeking Alpha
Steve Brozak: Big-Picture Biotech Stocks Rule The Future 12:51 a.m. Sept. 5, 2014 - Seeking Alpha
Navidea inks China commercialization deal 7:36 a.m. Sept. 4, 2014 - Seeking Alpha
10-Q: NAVIDEA BIOPHARMACEUTICALS, INC. 2:57 p.m. Aug. 11, 2014 - Edgar Online - (EDG = 10Q, 10K)
Navidea Biopharmaceuticals, Inc's (NAVB) CEO Michael Goldberg on Q2 2014 Results - Earnings Call Transcript 3:20 p.m. Aug. 6, 2014 - Seeking Alpha
Loading more headlines...
Press Releases on NAVB
Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status;Platinum Partners Reaffirms Commitment to Line of Credit 7:30 a.m. Nov. 11, 2014 - BusinessWire - BZX
Navidea Announces Third Quarter 2014 Financial Results 7:34 a.m. Nov. 6, 2014 - BusinessWire - BZX
Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European Association of Nuclear Medicine and European Society of Surgical Oncology Meetings 6:32 a.m. Oct. 30, 2014 - BusinessWire - BZX
Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014 6:35 a.m. Oct. 29, 2014 - BusinessWire - BZX
Navidea Announces Rick Gonzalez as New Chief Executive Officer 7:04 a.m. Oct. 15, 2014 - BusinessWire - BZX
FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid Tumors 6:03 a.m. Oct. 15, 2014 - BusinessWire - BZX
Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 7:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor Conference September 30th 2:36 p.m. Sept. 29, 2014 - BusinessWire - BZX
Navidea Biopharmaceuticals Brief Analyst Report by Small Cap Street and BrokerBank Securities, Inc. 6:30 a.m. Sept. 29, 2014 - PR Newswire - PRF
Navidea’s Lymphoseek® Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck Cancers 6:27 a.m. Sept. 26, 2014 - BusinessWire - BZX
Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer 6:30 a.m. Sept. 23, 2014 - BusinessWire - BZX
Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers 3:07 p.m. Sept. 18, 2014 - BusinessWire - BZX
Agilis Biotherapeutics Names Dr. Mark J. Pykett as President and Chief Executive Officer 12:00 p.m. Sept. 10, 2014 - BusinessWire - BZX
Navidea Enters Lymphoseek® Development and Commercialization Agreement for China 6:31 a.m. Sept. 4, 2014 - BusinessWire - BZX
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc. 8:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million 10:33 p.m. Aug. 6, 2014 - BusinessWire - BZX
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014 8:37 a.m. July 29, 2014 - BusinessWire - BZX
Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results 2:44 p.m. July 17, 2014 - BusinessWire - BZX
Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases 6:30 a.m. July 16, 2014 - BusinessWire - BZX
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014 4:06 p.m. July 2, 2014 - BusinessWire - BZX
Loading more headlines...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Humberto Quintanar Strengthens McKinley Irvin's Seattle Team

Humberto Quintanar Makes His Move In a world where legal battles can shake lives to the core, McKinley Irvin is throwing another heavyweight into the ring. They’ve just pulled in Humberto Quintanar, a guy who knows his way around a courtroom like a cabbie knows a city's backstreets. This isn't just another seat-fillin' lawyer; Quintanar packs years of experience as a...

Approved Oil Secures Long-Term NYC Fuel Terminal Deal

Approved Oil Locks in Future with Sunoco Deal Amidst the contraction of New York City's fuel terminal landscape, securing a consistent lifeline to crucial infrastructure feels like striking gold. Approved Oil just locked down an agreement with Sunoco for a new terminal location that'll last deep into the 2040s, and it's about more than just securing a spot on the...

Columbia Distributing Expands to Alaska: A Growth Move

Alaska's Entry: Columbia's New Frontier When Columbia Distributing dives into a new territory, you know they're serious about growth. This latest move sees them planting their flag in Alaska, finally completing a strategic vision that's been brewing for a while. Four-State Strategy Comes to Fruition The transaction with Republic National Distributing Company (RNDC) is no...

Gildan's Troubling Legal Struggles: Investor Action Alert

Gildan's Bumpy Ride: Legal Woes Unfold Well, folks, seems like Gildan Activewear Inc. (NYSE:GIL) is in for a bumpy ride, and not the kind that makes you feel alive, I tell ya. They've been slapped with a class action lawsuit, and the news ain't pretty. Accusations are flying hot about how they've been playing fast and loose with their financials. The Allegations: Channel...

DropGenie Nets $5M to Boost Functional Biology Reach

DropGenie Scores Big with Fresh Financing Boost Out of the Montreal wilderness, DropGenie is charging forward with a fresh $5 million injection in Seed+ financing. This isn't just loose change; it's a ticket to accelerating their mission of advancing functional biology platforms and beefing up data partnerships. You know, the kind of partnerships that even the suits in...

Skechers Facing Class Action: Investors Urged to Act

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Ernesta Expands Southeast Reach with Atlanta Showroom

Ernesta's Southeast Play: The Atlanta Showroom Here's something to turn heads in the world of custom home design—Ernesta has just set up shop in Atlanta, a move that speaks volumes about their ambitions in the Southeast market. This isn't just about selling a few more rugs; it's a calculated step into a region ripe with design potential and a hunger for bespoke home...

Gildan Activewear Faces Major Class Action Lawsuit

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Bertram Capital Backs MCE's Expansive Growth Vision

A Strategic Move for Bertram Capital Right on the heels of seasoned market moves, Bertram Capital has thrown its support behind Motion & Control Enterprises (MCE). This isn't just another portfolio addition; it's a calculated step into the complex world of industrial distribution, partnering with a company renowned for its prowess in engineered solutions. If you've ever...